Search hospitals
>
Illinois
>
Galesburg
Illinois CancerCare-Galesburg
Claim this profile
Galesburg, Illinois 61401
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Breast cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
410 reported clinical trials
2 medical researchers
Summary
Illinois CancerCare-Galesburg is a medical facility located in Galesburg, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Galesburg is involved with conducting 410 clinical trials across 477 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.
Area of expertise
Breast Cancer
Illinois CancerCare-Galesburg has run 71 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Illinois CancerCare-Galesburg has run 69 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Bryan A. Faller
Crossroads Cancer Center
7 years of reported clinical research
James L. Wade
Decatur Memorial Hospital
4 years of reported clinical research
Clinical Trials running at Illinois CancerCare-Galesburg
Lung Cancer
Prostate Cancer
Breast Cancer
Cancer
Breast cancer
Pancreatic Cancer
Colorectal Cancer
Bladder Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting
2 awards
Phase 3
4 criteria
Ceralasertib + Durvalumab
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting
2 awards
Phase 3
10 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Illinois CancerCare-Galesburg?
Illinois CancerCare-Galesburg is a medical facility located in Galesburg, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Galesburg is involved with conducting 410 clinical trials across 477 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.
Where is Illinois CancerCare-Galesburg located?
**Illinois CancerCare - Galesburg Location** - **Address:** 336 Home Blvd, Galesburg, IL 61401 - **Office Hours:** Monday-Friday, 8:00 AM - 5:00 PM - **Lab Hours:** Monday-Friday, 7:30 AM - 4:00 PM
Who should I call to ask about financial aid or insurance network?
**Illinois CancerCare-Galesburg Contact Information** **Financial Assistance:** - Phone: (800) 421-5700 - Email: OSF@ElevatePFS.com **Insurance:** - Phone: (309) 243-3000 or (866) 662-6564 - Address: 8940 N Wood Sage Rd, Peoria, IL 61615-7828 **General Information:** - Phone: (217) 383-3311
What insurance does Illinois CancerCare-Galesburg accept?
Illinois CancerCare-Galesburg accepts various insurance plans. For the most accurate and up-to-date information on accepted insurance plans, please contact the hospital directly or visit their website.
What awards or recognition has Illinois CancerCare-Galesburg received?
Illinois CancerCare-Galesburg, located in Galesburg, Illinois, is a leading hospital recognized by the Alliance for Clinical Trials in Oncology for its outstanding clinical research enrollment. It is a proud member of Heartland Cancer Research NCORP, renowned for leading the nation in cancer research participation. Additionally, it has earned recognition from the Quality Oncology Practice Initiative (QOPI®) Certification Program, highlighting its commitment to the highest standards of quality in outpatient hematology-oncology care.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.